• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Edgewise Therapeutics Inc.

    3/3/25 4:06:08 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EWTX alert in real time by email
    S-8 1 tm257912d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 3, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8 REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    EDGEWISE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1725586

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    1715 38th Street

    Boulder, CO 80301

    (Address of Principal Executive Offices) (Zip Code)

     

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full title of the plan)

     

    Kevin Koch, Ph.D.

    President and Chief Executive Officer

    Edgewise Therapeutics, Inc.

    1715 38th Street

    Boulder, CO 80301

    (Name and address of agent for service)

     

    (720) 262-7002

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Kenneth A. Clark

    Tony Jeffries

    Jennifer Knapp

    Wilson Sonsini Goodrich & Rosati

    Professional Corporation

    1155 Canyon Blvd., Suite 400

    Boulder, CO 80302-5148

    (303) 256-5900

    R. Michael Carruthers

    Chief Financial Officer

    Edgewise Therapeutics, Inc.

    1715 38th Street

    Boulder, CO 80301

    (720) 262-7002

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   x   Accelerated filer   ¨
           
    Non-accelerated filer   ¨   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    Edgewise Therapeutics, Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):

     

    (1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 3, 2025;

     

    (2)The Registrant’s Current Report on Form 8-K filed with the Commission on January 22, 2025; 

     

    (3)All other reports filed with the Commission pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above; and

     

    (4)The description of the Registrant’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-40236) filed with the Commission on March 17, 2021, including any amendment or report filed for the purpose of updating such description.

      

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in the corporation’s best interests, and, with respect to any criminal action, had no reasonable cause to believe the person’s actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise. The Amended and Restated Certificate of Incorporation of the Registrant provides for the indemnification of the Registrant’s directors to the fullest extent permitted under the Delaware General Corporation Law. In addition, the Amended and Restated Bylaws of the Registrant require the Registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the Registrant, or is or was a director or officer of the Registrant serving at the Registrant’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.

     

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except (1) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions by a director or officer not in good faith or which involve intentional misconduct or a knowing violation of law, (3) with respect to a director, for payments of unlawful dividends or unlawful stock repurchases or redemptions, (4) for any transaction from which the director or officer derived an improper personal benefit or (5) for claims against an officer in any action by or in the right of the corporation. The officers who may be exculpated pursuant to Section 102(b)(7) of the Delaware General Corporation Law are only officers who at the time of an act or omission as to which liability is asserted are deemed to have consented to service of process to the registered agent of the corporation under Delaware law. The Amended and Restated Certificate of Incorporation of the Registrant provides that the Registrant’s directors and officers shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director or officer to the fullest extent permitted by the Delaware General Corporation Law and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of the Registrant’s directors and officers shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

     

    Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

     

     

     

    As permitted by the Delaware General Corporation Law, the Registrant has entered into separate indemnification agreements with each of the Registrant’s directors and certain of the Registrant’s officers which require the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain other employees.

     

    The Registrant expects to obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.

     

    These indemnification provisions and the indemnification agreements entered into between the Registrant and the Registrant’s officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

            Incorporated by Reference
    Exhibit
    Number
      Description   Form   File No.   Exhibit   Filing Date
    4.2   Specimen common stock certificate of the Registrant   S-1/A   333-253923   4.2   3/22/2021
    5.1*   Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation                
    10.1   2021 Equity Incentive Plan and forms of agreements thereunder   S-1/A   333-253923   10.3   3/22/2021
    10.2   Form of Restricted Stock Unit Agreement   10-Q   001-40236   10.2   5/11/2023
    10.3   2021 Employee Stock Purchase Plan and forms of agreements thereunder   10-K   001-40236   10.5   2/23/2023
    23.1*   Consent of Independent Registered Public Accounting Firm                
    23.2*   Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)                
    24.1*   Power of Attorney (contained on signature page hereto)                
    107*   Filing Fee Table                

     

    *Filed herewith.

     

    Item 9 Undertakings.

     

    (a)            The undersigned Registrant hereby undertakes:

     

    (1)       to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)       to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

     

     

     

    (ii)      to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement; and

     

    (iii)     to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)       that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)       to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)           The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, Colorado, on March 3, 2025.

     

    EDGEWISE THERAPEUTICS, INC.  
         
    By: /s/ Kevin Koch  
      Kevin Koch, Ph.D.  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin Koch, Ph.D., R. Michael Carruthers and John R. Moore as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Kevin Koch   President, Chief Executive Officer and Director (Principal Executive Officer)   March 3, 2025
    Kevin Koch, Ph.D.        
             
    /s/ R. Michael Carruthers Chief Financial Officer (Principal Financial and Accounting Officer)   March 3, 2025
    R. Michael Carruthers        
             
    /s/ Peter Thompson   Co-Founder, Chairman and Director   March 3, 2025
    Peter Thompson, M.D.        
             
    /s/ Alan Russell   Chief Scientific Officer and Director   March 3, 2025
    Alan Russell, Ph.D.        
             
    /s/ Laura A. Brege   Director   March 3, 2025
    Laura A. Brege        
             
    /s/ Badreddin Edris   Co-Founder and Director   March 3, 2025
    Badreddin Edris, Ph.D.        
             
    /s/ Jonathan Fox   Director   March 3, 2025
    Jonathan Fox, M.D., Ph.D., FACC        
             
    /s/ Arlene Morris   Director   March 3, 2025
    Arlene Morris        
             
    /s/ Jonathan Root   Director   March 3, 2025
    Jonathan Root, M.D.        

      

     

     

    Get the next $EWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EWTX

    DatePrice TargetRatingAnalyst
    4/30/2025$41.00Buy
    Guggenheim
    4/2/2025$14.00Sector Outperform → Sector Perform
    Scotiabank
    3/7/2025$50.00Sector Outperform
    Scotiabank
    1/22/2025$30.00Hold
    Stifel
    11/22/2024$45.00Outperform
    Evercore ISI
    3/7/2024$48.00Overweight
    Piper Sandler
    5/1/2023Buy
    Truist
    8/25/2022$5.00Neutral → Sell
    Goldman
    More analyst ratings

    $EWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – –  On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo., May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results

      5/8/25 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions. The deal

      4/2/25 6:22:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

      – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from th

      4/2/25 6:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Russell Alan J converted options into 5,209 shares and sold $25,520 worth of shares (1,551 units at $16.45), increasing direct ownership by 25% to 18,521 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:58 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Moore John R converted options into 5,209 shares and sold $31,757 worth of shares (1,930 units at $16.45), increasing direct ownership by 101% to 6,531 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Koch Kevin converted options into 10,417 shares and sold $70,358 worth of shares (4,276 units at $16.45), increasing direct ownership by 42% to 20,619 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:20 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Edgewise Therapeutics with a new price target

      Guggenheim initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $41.00

      4/30/25 8:12:14 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics downgraded by Scotiabank with a new price target

      Scotiabank downgraded Edgewise Therapeutics from Sector Outperform to Sector Perform and set a new price target of $14.00

      4/2/25 11:46:29 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Edgewise Therapeutics with a new price target

      Scotiabank initiated coverage of Edgewise Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

      3/7/25 8:04:46 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:42:30 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:33:31 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thompson Peter A. bought $4,999,995 worth of shares (454,545 units at $11.00) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      1/25/24 4:32:07 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Leadership Updates

    Live Leadership Updates

    See more

    $EWTX
    SEC Filings

    See more
    • Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

      Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin

      5/7/24 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

      – President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos

      3/6/23 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

      – Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President o

      12/20/22 9:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Edgewise Therapeutics Inc.

      10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:05:22 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:00:45 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Edgewise Therapeutics Inc.

      DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      4/29/25 4:16:25 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Financials

    Live finance-specific insights

    See more
    • Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos

      9/11/22 5:00:00 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month

      6/20/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

      - Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi

      6/16/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 6:22:11 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:31:39 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edgewise Therapeutics Inc.

      SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:14:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care